The company's proprietary balloon catheter and pump controller are designed to limit venous return to the heart and treat fundamental ADHF clinical hemodynamic targets via intermittent superior vena cava occlusion. ADHF is a leading cause of morbidity and mortality worldwide, responsible for over 1 million hospitalizations per year in the US alone. Despite available treatments, ADHF remains associated with a poor quality of life and high mortality. preCARDIA aims to improve patients’ quality of life through pioneering clinically advanced technology and offers an alternative solution for physicians and their patients suffering from ADHF.